Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241162 · ClinicalTrials.gov registry record · Phase 1
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
A Phase 1 study of Neuroblastoma and Rhabdomyosarcoma, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01241162: Completed Phase 1 study of Neuroblastoma and Rhabdomyosarcoma, sponsored by University of Louisville.
NCT01241162 is a Phase 1 study of Neuroblastoma and Rhabdomyosarcoma that has completed, run by University of Louisville. The registered enrollment target is 19 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01241162, a Phase 1 study of Neuroblastoma and Rhabdomyosarcoma, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.
Primary Outcome
Tolerance to DAC, at at least 50% dosing, and 3 of the 4 planned vaccinations during the first two cycles.
Conditions Studied
Interventions
- BIOLOGICAL Autologous dendritic cell vaccine with adjuvant
Study Locations (1)
Kentucky
- University of Louisville, Kosair Charities Pediatric Clinical Research Unit - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
What the finished NCT01241162 record still lists
NCT01241162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Autologous dendritic cell vaccine with adjuvant is the first listed.
NCT01241162 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT01241162 about?
NCT01241162 is a clinical study titled "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma". This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.
What is the current status of trial NCT01241162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-08. Estimated completion is 2016-10.
What conditions does trial NCT01241162 study?
This clinical trial studies the following conditions: Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Ewing's Sarcoma, Osteogenic Sarcoma.
What interventions are being tested in trial NCT01241162?
The interventions under investigation include: Autologous dendritic cell vaccine with adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01241162?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01241162 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01241162's enrollment target sits among peer trials
19 75th of 94 higher than 19 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia